• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

European League Against Rheumatism (EULAR) - Articles and news items

biosimilar

Study finds biosimilar switching not suitable for all patients

Industry news / 10 June 2016 / Victoria White, Digital Content Producer

A study presented at EULAR showed that when antibodies develop in response to the infliximab, they also cross-react with the biosimilar of infliximab…

bimekizumab

Bimekizumab demonstrates positive results in patients with psoriatic arthritis

Industry news / 10 June 2016 / Victoria White, Digital Content Producer

In a Phase Ib study, bimekizumab showed fast and sustained efficacy on disease activity measures in both skin and joints and was well-tolerated…

baracitinib

New data for baricitinib in rheumatoid arthritis presented at EULAR

Industry news / 9 June 2016 / Victoria White, Digital Content Producer

Findings from the RA-BEYOND study demonstrate that baricitinib was superior to placebo at inhibiting progressive radiographic joint damage…

biosimilars

Efficacy and safety of Biogen’s anti-TNF biosimilars presented at EULAR

Industry news / 9 June 2016 / Victoria White, Digital Content Producer

Data demonstrating long-term comparable efficacy, safety and immunogenicity of Benepali (etanercept) and Flixabi (infliximab) have been presented at EULAR…

Benlysta

Greater response with GSK’s Benlysta vs placebo in SLE study

Industry news / 8 June 2016 / Victoria White, Digital Content Producer

Patients with SLE experienced a significantly greater response to treatment with Benlysta administered via subcutaneous injection compared to placebo…

Sirukumab

Sirukumab meets both co-primary endpoints in rheumatoid arthritis study

Industry news / 8 June 2016 / Victoria White, Digital Content Producer

The SIRROUND-D study met both co-primary endpoints in evaluating treatment with sirukumab in adult patients with active rheumatoid arthritis…

cosentyx

Novartis plans head-to-head studies of Cosentyx versus Humira

Industry news / 8 June 2016 / Victoria White, Digital Content Producer

Long-term analyses suggest Cosentyx may lead to higher responses than Humira in improving signs and symptoms of ankylosing spondylitis and psoriatic arthritis…

astrazeneca-lesinurad

AstraZeneca announces Phase III results for lesinurad in combination with febuxostat in patients with tophaceous gout

Industry news / 15 June 2015 / Victoria White

AstraZeneca presented results from its Phase III trial investigating lesinurad in combination with febuxostat in patients with tophaceous gout at EULAR 2015…

cimzia arthritis x-ray hands bones

Positive results from Phase 3 study evaluating Cimzia in DMARD-naïve rheumatoid arthritis patients

Industry news / 15 June 2015 / Victoria White

UCB has announced data from a Phase 3 study that showed the substantial benefits, at 52 weeks, of adding Cimzia to optimised methotrexate treatment…

chickenpox

Chickenpox vaccine can be effective and safe even in children with paediatric rheumatic disease

Industry news / 12 June 2015 / Victoria White

Results from a new study show that the chickenpox vaccine can be safe even in children with rheumatic disease receiving immunosuppression treatment…

eular

Janssen to present 17 abstracts in ankylosing spondylitis, rheumatoid arthritis, psoriatic arthritis and psoriasis at EULAR

Industry news / 11 June 2015 / Victoria White

Seventeen Janssen Immunology abstracts in ankylosing spondylitis, rheumatoid arthritis, psoriatic arthritis and psoriasis, will be presented at EULAR…

nsaids

Non-steroidal anti-inflammatory drugs (NSAIDs) inhibit ovulation after just 10 days

Industry news / 11 June 2015 / Victoria White

The results of a study presented at EULAR 2015 show that NSAIDs, such as diclofenac, significantly inhibit ovulation in women with mild musculoskeletal pain…

 

Webinar: Use of MicroNIR to optimise fluid bed drying and to reduce waste at tablet compressionWATCH NOW
+ +